---
layout: default
title: Zanubrutinib
description: "Zanubrutinib çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 6 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 201
evidence_level: L3
indication_count: 6
---

# Zanubrutinib

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>6</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Zanubrutinibï¼šå¾ B ç´°èƒæ·‹å·´ç˜¤åˆ°éª¨é«“æ€§ç™½è¡€ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Zanubrutinib å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Zanubrutinib åŸæœ¬ç”¨æ–¼æ²»ç™‚è¢«å¥—ç´°èƒæ·‹å·´ç˜¤ã€è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ç­‰ B ç´°èƒæƒ¡æ€§è…«ç˜¤ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**éª¨é«“æ€§ç™½è¡€ç—… (myeloid leukemia)** æœ‰æ•ˆï¼Œ
æœ‰ **2 å€‹è‡¨åºŠè©¦é©—**å’Œ **9 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è¢«å¥—ç´°èƒæ·‹å·´ç˜¤ (MCL)ã€è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ (WM)ã€CLL/SLLã€é‚Šç·£å€æ·‹å·´ç˜¤ã€æ¿¾æ³¡æ€§æ·‹å·´ç˜¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | myeloid leukemiaã€vertebral anomalies and variable endocrine and T-cell dysfunctionã€ganglioneuroblastoma (disease)ã€è…¹è†œå¾Œè…«ç˜¤ã€Ewing sarcomaã€ç¥ç¶“æ¯ç´°èƒç˜¤ |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.65% |
| è­‰æ“šç­‰ç´š | L2 (æœ‰è‡¨åºŠè©¦é©—æ”¯æŒ) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 å¼µ (æœ‰æ•ˆ) |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. myeloid leukemia</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.65%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Zanubrutinib æ˜¯é«˜é¸æ“‡æ€§çš„å¸ƒé­¯é “é…ªæ°¨é…¸æ¿€é…¶ (BTK) æŠ‘åˆ¶åŠ‘ã€‚</p>
<p>BTK åœ¨ B ç´°èƒå—é«” (BCR) è¨Šè™Ÿå‚³éä¸­æ‰®æ¼”é—œéµè§’è‰²ï¼ŒæŠ‘åˆ¶ BTK å¯é˜»æ–·æƒ¡æ€§ B ç´°èƒçš„å¢æ®–èˆ‡å­˜æ´»ã€‚</p>

<p><strong>ä½œç”¨æ©Ÿè½‰ï¼š</strong></p>
<ul>
<li>æŠ‘åˆ¶ BTK (Bruton tyrosine kinase)ï¼ŒIC50 ç´„ 20 nM</li>
<li>ç›¸è¼ƒæ–¼ ibrutinibï¼Œå…·æœ‰æ›´é«˜çš„ BTK é¸æ“‡æ€§</li>
<li>è¼ƒå°‘ off-target æ•ˆæ‡‰ï¼Œå¿ƒæˆ¿é¡«å‹•ç­‰å‰¯ä½œç”¨è¼ƒä½</li>

</ul>
<p>é›–ç„¶ BTK ä¸»è¦è¡¨ç¾æ–¼ B ç´°èƒï¼Œä½†è¿‘å¹´ç ”ç©¶ç™¼ç¾ BTK åœ¨æŸäº›éª¨é«“æ€§æƒ¡æ€§è…«ç˜¤ä¸­ä¹Ÿæœ‰è¡¨ç¾ï¼Œ</p>
<p>é€™å¯èƒ½æ˜¯é æ¸¬ zanubrutinib å°éª¨é«“æ€§ç™½è¡€ç—…æœ‰æ•ˆçš„æ©Ÿè½‰åŸºç¤ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04477291" target="_blank">NCT04477291</a></td><td>PHASE1</td><td>TERMINATED</td><td>45</td><td>A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05665530" target="_blank">NCT05665530</a></td><td>PHASE1</td><td>COMPLETED</td><td>86</td><td>A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Mono...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39647999/" target="_blank">39647999</a></td><td>2025</td><td>Article</td><td>Journal of clinical oncology :</td><td>Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-NaÃ¯ve ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40334067/" target="_blank">40334067</a></td><td>2025</td><td>Article</td><td>Blood advances</td><td>Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40829104/" target="_blank">40829104</a></td><td>2026</td><td>Article</td><td>Blood advances</td><td>Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36400069/" target="_blank">36400069</a></td><td>2023</td><td>Article</td><td>The Lancet. Haematology</td><td>Zanubrutinib in patients with previously treated B-cell malignancies intolerant ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34959482/" target="_blank">34959482</a></td><td>2021</td><td>Article</td><td>Pharmaceutics</td><td>The TKI Era in Chronic Leukemias.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36402930/" target="_blank">36402930</a></td><td>2023</td><td>Article</td><td>Leukemia</td><td>Managing WaldenstrÃ¶m&#x27;s macroglobulinemia with BTK inhibitors.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36325357/" target="_blank">36325357</a></td><td>2022</td><td>Article</td><td>Frontiers in immunology</td><td>Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38288815/" target="_blank">38288815</a></td><td>2024</td><td>Article</td><td>Anti-cancer agents in medicina</td><td>An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-20...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37150651/" target="_blank">37150651</a></td><td>2023</td><td>Article</td><td>Clinical lymphoma, myeloma &amp; l</td><td>Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhi...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. vertebral anomalies and variable endocrine and T-cell dysfunction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.38%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. ganglioneuroblastoma (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.36%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. retroperitoneal neoplasm</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.30%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. Ewing sarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. neuroblastoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38288815/" target="_blank">38288815</a></td><td>2024</td><td>Article</td><td>Anti-cancer agents in medicina</td><td>An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-20...</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ ¸å‡†æ—¥æœŸ |
|---------|------|------|-------------|---------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028160è™Ÿ | ç™¾æ‚…æ¾¤è† å›Š 80 æ¯«å…‹ | è† å›ŠåŠ‘ | è‡ºç£ç™¾æ¿Ÿç¥å·æœ‰é™å…¬å¸ | 2021/09/15 |

**æ ¸å‡†é©æ‡‰ç—‡ï¼š**
1. å…ˆå‰æ›¾æ¥å—è‡³å°‘ä¸€ç¨®æ²»ç™‚çš„è¢«å¥—ç´°èƒæ·‹å·´ç˜¤ (MCL) æˆäººç—…äºº
2. è¯æ°å·¨çƒè›‹ç™½è¡€ç—‡ (WM) æˆäººç—…äºº
3. å…ˆå‰æ›¾æ¥å—è‡³å°‘ä¸€ç¨®æŠ— CD20 ç™‚æ³•çš„å¾©ç™¼æˆ–é ‘å›ºå‹é‚Šç·£å€æ·‹å·´ç˜¤ (MZL) æˆäººç—…äºº
4. æ…¢æ€§æ·‹å·´çƒæ€§ç™½è¡€ç—… (CLL)/å°æ·‹å·´çƒæ€§æ·‹å·´ç˜¤ (SLL) æˆäººç—…äºº
5. ä½µç”¨ obinutuzumab é©ç”¨æ–¼å…ˆå‰æ›¾æ¥å—è‡³å°‘ 2 ç¨®æ²»ç™‚çš„æ¿¾æ³¡æ€§æ·‹å·´ç˜¤ (FL) æˆäººç—…äºº

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | æ¨™é¶æ²»ç™‚è—¥ç‰© (éå‚³çµ±ç´°èƒæ¯’æ€§) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä¸­åº¦ (å—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ã€è¡€å°æ¿æ¸›å°‘) |
| å‡ºè¡€é¢¨éšª | éœ€æ³¨æ„ï¼Œå°¤å…¶èˆ‡æŠ—å‡è¡€åŠ‘ä½µç”¨æ™‚ |
| ç›£æ¸¬é …ç›® | CBC (å«åˆ†é¡)ã€è‚åŠŸèƒ½ã€å‡ºè¡€å¾µå…† |
| è™•ç½®é˜²è­· | å£æœè—¥ç‰©ï¼Œä¾ä¸€èˆ¬è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è—¥ç‰©äº¤äº’ä½œç”¨ (Major)ï¼š**

| è—¥ç‰©é¡åˆ¥ | ä»£è¡¨è—¥ç‰© | äº¤äº’ä½œç”¨æ©Ÿè½‰ |
|---------|---------|-------------|
| æŠ—å‡è¡€åŠ‘/æŠ—è¡€å°æ¿ | Warfarin, Apixaban, Clopidogrel, Aspirin | å¢åŠ å‡ºè¡€é¢¨éšª |
| CYP3A å¼·æ•ˆæŠ‘åˆ¶åŠ‘ | Ketoconazole, Clarithromycin, Cobicistat | å¢åŠ  zanubrutinib è¡€ä¸­æ¿ƒåº¦ |
| CYP3A å¼·æ•ˆèª˜å°åŠ‘ | Enzalutamide, Apalutamide, Mitotane | é™ä½ zanubrutinib è¡€ä¸­æ¿ƒåº¦ |
| å…¶ä»– BTK æŠ‘åˆ¶åŠ‘ | Ibrutinib, Acalabrutinib | è—¥ç†ä½œç”¨é‡ç–Š |
| å…ç–«æŠ‘åˆ¶åŠ‘ | Adalimumab, Etanercept, Infliximab | å¢åŠ æ„ŸæŸ“é¢¨éšª |

**æ³¨æ„äº‹é …ï¼š**
- æ¥å—æ‰‹è¡“å‰éœ€æš«åœä½¿ç”¨ (è¡“å‰è‡³å°‘ 3-7 å¤©)
- B å‹è‚ç‚å†æ´»åŒ–é¢¨éšªï¼Œéœ€ç›£æ¸¬ HBsAg/anti-HBc
- å¿ƒæˆ¿é¡«å‹•é¢¨éšªè¼ƒ ibrutinib ä½ï¼Œä½†ä»éœ€ç›£æ¸¬


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Arrhythmias, Cardiac** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€æ„ŸæŸ“ã€‚

**Hemorrhage** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Pancytopenia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€è²§è¡€ã€‚

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Infections** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‘¡è„æŸšæ±** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚å»ºè­°ç©ºè…¹æœç”¨ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é›–ç„¶ zanubrutinib çš„ä¸»è¦ä½œç”¨åœ¨ B ç´°èƒï¼Œä½†å…¶åœ¨è¡€æ¶²æƒ¡æ€§è…«ç˜¤ä¸­çš„å»£æ³›ç™‚æ•ˆå·²ç²è­‰å¯¦ã€‚
é‡å°éª¨é«“æ€§ç™½è¡€ç—…çš„é æ¸¬æœ‰åˆæ­¥è‡¨åºŠè©¦é©—æ”¯æŒï¼Œä½†é€™äº›è©¦é©—ä¸»è¦æ¢è¨è¯åˆç”¨è—¥è€Œéå–®ç¨ä½¿ç”¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- ç¢ºèª BTK åœ¨éª¨é«“æ€§ç™½è¡€ç—…ä¸­çš„è¡¨ç¾èˆ‡åŠŸèƒ½
- è¨­è¨ˆå°ˆé–€é‡å°éª¨é«“æ€§ç™½è¡€ç—…çš„ Phase 1/2 è‡¨åºŠè©¦é©—
- è©•ä¼°èˆ‡ç¾æœ‰éª¨é«“æ€§ç™½è¡€ç—…æ²»ç™‚è—¥ç‰©çš„è¯åˆæ•ˆæœ
- å»ºç«‹ç”Ÿç‰©æ¨™è¨˜é æ¸¬å¯èƒ½å—ç›Šçš„æ‚£è€…äºç¾¤

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Tizanidine]({{ "/drugs/tizanidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Denosumab]({{ "/drugs/denosumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cerliponase Alfa]({{ "/drugs/cerliponase_alfa/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Insulin Lispro]({{ "/drugs/insulin_lispro/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ferrous Gluconate]({{ "/drugs/ferrous_gluconate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Zanubrutinibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/zanubrutinib/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_zanubrutinib,
  title = {Zanubrutinibè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/zanubrutinib/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
